Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 29-33

  Aarts, Frits ^a   Hendriks, Thijs ^a   Eek, Annemarie ^a   Oyen, Wim J G ^a   Bleichrodt, Robert P ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytoreductive surgery; Galactosylation; Peritoneal carcinomatosis; Radioimmunotherapy

Indexed keywords

CYANOMETHYL 2,3,4,6 TETRA O ACETYL 1 THIO BETA DEXTRO GALACTOPYRANOSIDE; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MG1; PYRANOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; AREA UNDER THE CURVE; ARTICLE; CARCINOMATOUS PERITONITIS; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG UPTAKE; GALACTOSYLATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GALACTOSE; MALE; MICE; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RATS; TISSUE DISTRIBUTION;

EID: 60849120135     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0521     Document Type: Article

References (20)

1. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565.
2. Heldin CH. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806.
3. Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 1997;38:409.
4. Koppe MJ, Hendriks T, Boerman OC, et al. Radioimmunotherapy is an effective adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis of colonic origin. J Nucl Med 2006;47:1867.
5. Aarts F, Koppe MJ, Hendriks T, et al. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2007;14:533.
6. Aarts F, Hendriks T, Boerman OC, et al. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol 2007;14:3274.
7. Boerman OC, van Schaijk FG, Oyen WJ, et al. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003;44:400.
8. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531.
9. Morell AG, Gregoriadis G, Scheinberg IH, et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971;246:1461.
10. Hagenaars M, Koelemij R, Ensink NG, et al. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metast 2000;18:281.
11. Dubois M, Gilles KA, Hamilton JK. Colorimetric method for determination of sugars and related substances. Annal Chem 1956;28:350.
12. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849.
13. Zedeck MS. A model system for studies of colon carcinogenesis: Tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst 1974;53:1419.
14. Lopes Cardozo AM, Gupta A, Koppe MJ, et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: An experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001;27:359.
15. Ong GL, Ettenson D, Sharkey RM, et al. Galactose-conjugated antibodies in cancer therapy: Properties and principles of action. Cancer Res 1991;51:1619.
16. Sharma SK, Bagshawe KD, Burke PJ, et al. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 1994;73:1114.
17. Colcher D, Esteban J, Carrasquillo JA, et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987;47:4218.
18. Koppe MJ, Soede AC, Pels W, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer 2003;106:965.
19. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer 2001;92:106.
20. 211At-labeled humanized monoclonal antibody A33. Cancer Biother Radiopharm 2007;22:480.